MNK (Update), TEVA, PFE
Mallinckrodt Public Limited Company
Healthcare
02/17/2015
Presented
| Date | 02/12/2015 |
| Price | $115.01 |
| Market Cap | $13.40B |
| Ent Value | $16.46B |
| P/E Ratio | N/A |
| Book Value | $43.64 |
| Div Yield | N/A |
| Shares O/S | 116.48M |
| Ave Daily Vol | 1,410,000 |
| Short Int | 7.15% |
Current
| Price | no data |
| Market Cap | no data |
| Mallinckrodt public limited company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging. The Specialty Pharmaceuticals segment provides Acthar, an injectable biopharmaceutical drug for use in various indications, including neurology, rheumatology, nephrology, and pulmonology; Ofirmev and Xartemis XR for pain indications; EXALGO extended-release tablets to treat chronic pain; and GABLOFEN injections for use in the management of spasticity of cerebral or spinal origin. It also offers generics and active pharmaceutical ingredients (API), such as hydrocodone and hydrocodone-containing tablets, oxycodone and oxycodone-containing tablets, and methylphenidate HCl extended-release tablets, as well as biologics, medicinal opioids, synthetic controlled substances, acetaminophen products, and other active ingredients. The Global Medical Imaging segment provides contrast media and delivery systems comprising ioversol and gadoversetamide injections for diagnostic imaging applications under the Optiray and Optimark brand names with pre-filled syringes and power injectors to the hospitals and imaging centers. It also offers nuclear imaging products consisting of technetium-99m generators under the Ultra-Technekow DTE brand; cold kits; and Octreoscan kits for localization of tumors. The company markets its products to physicians, pharmacists, pharmacy buyers, specialty pharmacies, radiologists, and radiology technicians, as well as distributes its products to drug wholesalers, retail pharmacy chains, hospital networks, ambulatory surgical centers, and governmental agencies; sells and distributes APIs directly or through distributors to other pharmaceutical companies; and markets and distributes nuclear imaging products to radiopharmacies and hospitals. Mallinckrodt public limited company is based in Dublin, Ireland. |
Please note, this is an update to Long - Mallinckrodt PLC, which was originally presented on 10/6/2014 ($91.32).
Publicly traded companies mentioned herein: AbbVie Inc (ABBV), Gilead Sciences Inc (GILD), Hospira Inc (HSP), Mallinckrodt PLC (MNK), Pfizer Inc (PFE), Teva Pharmaceutical Industries (TEVA)
Highlights
The presenter continues to see upside for shareholders of Mallinckrodt (MNK), and more generally said that he thinks “this is the seventh inning of the ball game,” suggesting that there may very well be more upside left for the specialty pharmaceuticals trade than skeptics believe is possible. “The healthcare sector is on fire for all the right reasons; 50% - 75% of the big drug companies (including biotechs) are in new product cycles and there are real changes in how drug development works.” And, these are “really important” products cycles (i.e., immunotherapy changes the way the body attacks cancer, and HepC can now be cured), which tend to last 10 years, he added. In addition to sticking with MNK, the presenter suggesting adding Teva Pharmaceuticals (TEVA) as a long position, and explained his reasoning for this and sticking with specialty pharma companies as follows:
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.